News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rebiotix Completes Enrollment In Phase 2 Clinical Trial Of New Drug For The Treatment Of Recurrent Clostridium Difficile-Associated Diarrhea


1/13/2014 11:12:19 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROSEVILLE, Minn.--(BUSINESS WIRE)--Rebiotix Inc. has announced that it has completed enrollment in the PUNCHâ„¢ CD Phase 2 clinical trial of RBX2660 (microbiota suspension) for the treatment of recurrent Clostridium difficile-associated diarrhea (CDAD). The study is the first of its kind prospective, multicenter clinical study to evaluate a non-antibiotic, live microbial drug product for the treatment of recurrent CDAD conducted using the same protocol at all sites.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
Rebiotix
 
 
Diarrhea

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES